Semaglutide has become one of the best-known GLP-1 receptor agonists, mainly because of its role in type 2 diabetes and chronic weight management. The scientific story behind it is broader than appetite control, and it begins in an unlikely place: Gila monster venom.
The useful view is simple. Semaglutide is a long-acting GLP-1 receptor agonist with strong clinical evidence for glucose control and weight reduction. Its possible role in cartilage and joint biology is a newer research question, not an established benefit.
How Gila monster venom shaped GLP-1 medicine
In the early 1990s, endocrinologist Dr John Eng identified a peptide called exendin-4 while studying the venom of the Gila monster. Exendin-4 shared similarities with human GLP-1, short for glucagon-like peptide-1, but had a key advantage for drug development: it remained active for much longer.
Natural GLP-1 is an important metabolic hormone, but it is broken down quickly in the body. That short activity window made it difficult to use directly as a practical medicine. Exendin-4 helped researchers see that a molecule could activate the GLP-1 receptor while lasting long enough to produce a meaningful therapeutic effect.
This discovery contributed to the development of exenatide, marketed as Byetta, which was approved for type 2 diabetes in 2005. Later GLP-1 medicines were engineered for longer activity, eventually leading to semaglutide, known through brands such as Ozempic, Wegovy and Rybelsus.
What semaglutide does as a GLP-1 receptor agonist
Semaglutide mimics native GLP-1 and binds to GLP-1 receptors. Its actions are discussed mainly in relation to metabolic regulation, especially glucose control, appetite and satiety.
According to the peptide profile, semaglutide can influence several processes:
It stimulates insulin secretion in a glucose-dependent manner.
It suppresses glucagon, a hormone involved in raising blood glucose.
It slows gastric emptying.
It reduces appetite through pathways involving the hypothalamus.
Semaglutide has a half-life of about 7 days, or 168 hours. That long duration is one reason once-weekly injectable formulations became practical. Oral semaglutide also exists, using absorption-enhancing tablet technology, although its administration requirements are more specific.
Where the evidence for semaglutide is strongest
The strongest evidence for semaglutide sits in type 2 diabetes and chronic weight management. It is FDA-approved for these uses, with large clinical programmes supporting its efficacy and safety profile in studied populations.
In weight management research, semaglutide 2.4 mg weekly was associated with substantial average weight loss. In the STEP 1 trial, involving 1,961 participants, average weight loss was 14.9% over 68 weeks, compared with 2.4% with placebo.
In diabetes research, the SUSTAIN programme reported average HbA1c reductions of about 1.5% to 1.8% across multiple trials. The reference profile also notes HbA1c reductions of 1.5% to 2% in clinical trials.
Cardiovascular outcomes are also part of the semaglutide evidence base. The SELECT cardiovascular outcomes study, with 17,604 participants, reported a 20% reduction in major adverse cardiovascular events over 5 years with 2.4 mg weekly. The peptide profile also notes established cardiovascular protection in high-risk diabetes populations.
Research areaWhat has been reportedEvidence statusChronic weight managementSTEP 1 reported 14.9% average weight loss over 68 weeks with semaglutide 2.4 mg weekly, compared with 2.4% with placebo.Strong clinical evidenceType 2 diabetesThe SUSTAIN programme reported average HbA1c reductions of about 1.5% to 1.8% across trials.Strong clinical evidenceCardiovascular outcomesSELECT reported a 20% reduction in major adverse cardiovascular events over 5 years.Strong outcome evidence in studied populationsCartilage and joint biologyEarly experimental work and a small human pilot study have raised questions about possible effects on cartilage thickness and chondrocyte metabolism.Early-stage research
Why weight loss changed the GLP-1 conversation
GLP-1 receptor agonists were first developed mainly for glucose control. Over time, the appetite and satiety effects became harder to ignore, especially as clinical trials reported meaningful weight reduction in many participants with obesity.
This shifted public attention toward weight loss. Scientifically, though, the conversation has widened. GLP-1 signalling is now explored in relation to cardiovascular health, kidney disease, metabolic syndrome, inflammation and reward-related behaviours.
That wider biology matters because semaglutide is not only discussed as a compound that reduces food intake. It is part of a signalling system that appears to interact with several metabolic pathways.
Could semaglutide affect cartilage?
Cartilage research is one of the more unexpected areas of GLP-1 investigation. Cartilage is difficult to restore once damaged because it has limited blood supply and poor natural repair capacity. This is one reason osteoarthritis and cartilage loss are challenging research areas.
The early question is whether GLP-1 signalling could influence cartilage biology directly. This is different from the simpler mechanical explanation that weight loss may reduce load on knees, hips and other weight-bearing joints.
Experimental work described in the source material included animal research and a small human pilot study. The findings suggested that semaglutide may be associated with improvements in cartilage thickness and joint health. Researchers also proposed that some effects might occur independently of weight reduction.
The proposed mechanism involves chondrocytes, the cells that maintain cartilage. If GLP-1 signalling affects how these cells manage energy and metabolism, it could influence the balance between cartilage maintenance and cartilage breakdown.
Early cartilage findings are interesting because they raise a biological question. They do not establish semaglutide as a cartilage-regeneration treatment.
Why cartilage metabolism matters
Cartilage is living tissue. Chondrocytes maintain the extracellular matrix that gives cartilage its strength and ability to absorb mechanical load.
When chondrocytes become metabolically dysfunctional, cartilage maintenance can fall behind cartilage breakdown. Osteoarthritis is therefore more complex than simple wear and tear. Inflammation, obesity, cellular metabolism and mechanical load can all be part of the process.
This is why the GLP-1 and cartilage question is attracting attention. If metabolic signalling affects cartilage cells directly, it could open new research directions. At this stage, that remains a hypothesis requiring larger and better-controlled studies.
Does semaglutide regrow cartilage?
No reliable claim can be made that semaglutide regrows cartilage in humans. The cartilage work discussed so far is early, and the human data highlighted in the source material came from a small pilot study.
Pilot studies are useful because they identify signals worth testing. They cannot prove that semaglutide regenerates cartilage, changes osteoarthritis outcomes or benefits specific patient groups.
Larger controlled studies would need to clarify several points:
whether measured cartilage changes are genuine and clinically meaningful
how much of any joint improvement is linked to weight loss
whether GLP-1 signalling has a direct effect on chondrocytes
whether any changes persist over time
which populations, if any, show the clearest response
For now, cartilage regeneration should be treated as an emerging research topic rather than an established semaglutide benefit.
Safety considerations in semaglutide research
Semaglutide has extensive clinical trial data, but that does not mean risks can be ignored. The peptide profile lists common side effects such as nausea, diarrhoea, vomiting, constipation and abdominal pain.
More serious warning signs include severe persistent abdominal pain, persistent vomiting that prevents fluid intake, symptoms that could suggest a thyroid tumour, severe allergic reaction, vision changes, severe hypoglycaemia when combined with insulin or sulfonylureas, and signs of kidney problems.
The profile also lists contraindications including a personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, pregnancy or breastfeeding, and a history of pancreatitis.
For research comparisons, product quality and documentation matter. Price alone is not a good basis for evaluating any peptide supplier SA listing. Product identity, concentration, storage requirements, supplier transparency and analytical documentation should all be considered.
Semaglutide research in South Africa
Interest in semaglutide and other GLP-1-related peptides SA searches has grown quickly. Some readers are comparing regulated medicines, while others are reviewing research compounds and supplier listings. Those are not the same category, and they should not be treated as interchangeable.
For anyone assessing where to buy peptides for laboratory or research use, the cheapest listing is not automatically the best-value option. A lower price can be less useful if the product details, storage information or analytical documentation are unclear.
Peptide Supermarket South Africa helps readers compare semaglutide prices and suppliers in one place, making it easier to assess value alongside the available product information. PeptideSupermarket®’s peptide price comparison page
Frequently asked questions
What is semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist. It mimics GLP-1 signalling and has been approved for type 2 diabetes and chronic weight management in specific formulations.
Why is semaglutide linked to Gila monster venom?
The link comes through exendin-4, a peptide identified in Gila monster venom by Dr John Eng. Exendin-4 helped show that GLP-1 receptor activation could be made longer-lasting, which influenced the development of GLP-1 medicines.
Is semaglutide only used for weight loss?
No. Semaglutide is also used in type 2 diabetes, where it supports glycaemic control. Research has also explored cardiovascular outcomes, metabolic health and other biological systems.
Does semaglutide help with cartilage damage?
Cartilage research is still early. Some experimental work and a small human pilot study have raised the possibility of effects on cartilage biology, but semaglutide has not been established as a cartilage-regeneration treatment.
What are common semaglutide side effects?
Commonly reported side effects include nausea, diarrhoea, vomiting, constipation and abdominal pain. The peptide profile also lists more serious warning signs that require medical attention in clinical contexts.
Where can I compare semaglutide prices in South Africa?
You can compare semaglutide listings on the Peptide Supermarket South Africa price comparison page. Use price together with supplier transparency, documentation and product details rather than price alone. Compare Semaglutide Prices
Research disclaimer
This content is for research and educational purposes only. It is not medical advice, and it does not recommend human consumption, self-administration, diagnosis or treatment.
Final thoughts
Semaglutide’s scientific story shows how unpredictable biomedical research can be. A venom-derived peptide helped shape GLP-1 medicine, and that drug class is now studied across glucose control, weight management, cardiovascular outcomes and newer questions such as cartilage biology.
The evidence is strongest for type 2 diabetes and chronic weight management. Cartilage research is intriguing because it may involve more than reduced mechanical load from weight loss, but it remains early.
To compare current Semaglutide prices in South Africa and review supplier options, visit the PeptideSupermarket®’s peptide price comparison page and look for the best-value option based on both price and product information.
Compare Semaglutide prices across the UK
Side-by-side prices from every trusted UK supplier stocking Semaglutide.
